Loxenatide
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Company n/r · Phase 2/3 · Completed · Enrollment 30
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| LNG-IUS | n/r | n/r | n/r | n/r |
| LOX+LNG-IUS | n/r | n/r | n/r | n/r |
Not shown
- LNG-IUS: endpoint not reported
- LOX+LNG-IUS: endpoint not reported